Renal cell carcinoma (RCC) is the third most common cancer in the urological system; however, the pathogenesis remains unknown. Accumulating evidence has demonstrated that long non-coding RNAs are dysregulated in various tumors and serves an important role in tumorigenesis and development.
Introduction
Renal cell carcinoma (RCC) is a common malignant tumor occurring mainly in adults, which accounts for ~3% of all malignant tumors in adults and 85% of all kidney tumors (1) (2) (3) .
RCC is the third most common cancer in urological system, after prostate and bladder cancer, and has the highest mortality rate (4, 5) . Furthermore, RCC is resistant to both chemotherapy and radiotherapy, but not to surgery (6, 7) . Patients are usually diagnosed for RCC when undergoing a medical examination or after having experienced some symptoms of RCC; currently, no biomarkers for the early diagnosis or targeted therapy of RCC exist. Therefore, it is necessary to improve the understanding of RCC and identify novel biomarkers for diagnosis, surveillance and targeted therapy for RCC.
Long non-coding RNA (lncRNA), at a length of >200 nucleotides, is identified as endogenous cellular RNAs lack of open reading frames of significant length (<100 amino acids) (6, 8) . With the development of gene sequencing, more and more lncRNAs have been identified (9) ; however, the functions of most lncRNAs remain unclear. Previous studies have revealed that certain lncRNAs may regulate gene expression at various levels and serve important roles in tumorigenesis and development (10) .
In the present study, the expression and function of lncRNA differentiation antagonizing non-protein coding RNA (DANCR) in RCC was investigated. A previous study revealed that lncRNA DANCR is upregulated in prostate cancer (11) , hepatocellular carcinoma (HCC) (12) and colorectal cancer (CRC) (13) . The present study detected the expression of DANCR in RCC tissues and adjacent paired normal tissues, and whether DANCR could affect the cellular function was also investigated.
Materials and methods
Sample collection. Paired RCC and adjacent normal tissues (n=24) were used in the present study and were collected from Peking University Shenzhen Hospital (Shenzhen, China). Tissues were immersed in RNAlater (Qiagen GmbH, Hilden, Germany) over 30 min while being dissected, then stored at -80˚C until further use. The adjacent normal tissues were 2 cm away from the RCC tissues and verified by pathological examination. All the tissues were reviewed and classified by hematoxylin and eosin (H&E) staining. Collection and usage of the samples were approved by the Ethics Committees of Peking University Shenzhen Hospital. Written informed consent was obtained from all patients.
Cell culture and transfection. The 786-O and ACHN RCC cell lines (American Type Culture Collection, Manassas, VA, USA) and the HEK-293 cell line (Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China) were used in this study. Cells were cultured at a temperature of 37˚C in a humidified incubator containing 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum, 1% antibiotics (100 µl/ml penicillin and 100 mg/ml streptomycin sulfates) and 1% glutamine (all from Gibco; Thermo Fisher Scientific, Inc.). Full-length lncRNA DANCR was subcloned into a pcDNA3.1 vector (GenePharma, Suzhou, China) and the vector (pcDNA3.1-DANCR) was verified by sequencing. For overexpression of lncRNA DANCR, synthesized pcDNA3.1-DANCR was transfected into cells using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.), which was mixed in the Opti-Minimum Essential Medium ® I Reduced Serum Medium (Gibco; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Mock pcDNA3.1 served as the negative control. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to detect the expression of DANCR in cells after transfection.
RNA extraction, cDNA synthesis and RT-qPCR. RNAiso Plus reagent (Takara Bio, Inc., Otsu, Japan) was used to extract RNA from tissues and cells. RT-qPCR was performed to obtain cDNA with 1 µg RNA using a PrimeScript TM RT reagent kit (Takara Bio, Inc.). Expression of lncRNA was detected by performing qPCR with Premix Ex Taq™ II (Takara Bio, Inc.) on a Roche Light Cycler 480 Real-Time PCR system. Cycling conditions were as follows: An initial predenaturation step at 95˚C for 1 min, followed by 40 cycles of denaturation at 95˚C for 10 sec, annealing at 60˚C for 30 sec and extension at 70˚C for 30 sec. GAPDH was used as an internal control and sequences of primers are presented in Table I . The ΔΔCq method (14) was used to analyze the expression of DANCR in tissues and cells. Experiments were performed in triplicate.
Cell proliferation assay. Cell proliferation was assessed by performing MTT and Cell Counting kit-8 (CCK-8) assays. Approximately 3,000 cells/well were seeded into a 96-well plate, and 12 h later the cells were transfected with pcDNA-3.1-DANCR or mock. At 0, 24, 48 and 72 h after transfection, MTT or CCK-8 was added into the wells according to the manufacturer's protocol. The optical density (OD) value of each well was measured using an ELISA microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) at a wave length of 490 nm. The experiments were performed in six and repeated at least three times.
Cell mobility assay. Cell scratch and Transwell assays were performed to assess cell mobility ability of 786-O and ACHN cells. Approximately 3x10 5 cells/well were seeded into a 6-well plate and 24 h later were transfected with pcDNA3.1-DANCR or mock. At 6 h later, the cell monolayer was scratched with a sterile 200 µl pipette tip to generate a line-shaped wound. Cells were then rinsed with phosphate-buffered saline to remove the floating cells, and then cells were cultured in DMEM supplemented with 5% FBS. At 0 and 24 h later, scratches were imaged with a digital camera system. The experiments were performed in triplicate and repeated three times.
Transwell invasive and migratory assays were performed to assess the cell migratory and invasive ability. Transwell chamber inserts (BD Biosciences, Franklin Lakes, NJ, USA) with (for migration) or without (for invasion) Matrigel (BD Biosciences) were used according to the manufacturer's protocol. Transfected cells in 200 µl DMEM were seeded at a density of 1x10 4 cells/well into the upper channel of the inserts. Cells were allowed to migrate for 36 h and invade for 48 h. The cells that had migrated or invaded to the bottom of the inserts were stained with crystal violet and counted using a microscope. The experiments were performed in in triplicate and repeated at least three times.
Flow cytometric assay. Flow cytometry was performed to detect the apoptotic rate of cells after transfection, with Alexa Fluor ® 488 Annexin V/Dead Cell Apoptosis kit (Invitrogen). After cells seeded for 24 h, the cells would be transfected with pcDNA3.1-DANCR or mock. 48 h after transfection all the cells would be harvested and stained according to the manufacturer's advice. Then flow cytometry (Beckman, Brea, CA, USA) was used to analyze the apoptosis rate. The experiments were performed in in triplicate and repeated at least 3 times.
Bioinformatics. Prediction of miRNAs that may target lncRNA DANCR was determined using computational algorithms based on seed regions between the miRNAs and lncRNA DANCR. The miRDB database (http://mirdb. org/miRDB/index.html) was used in the present study to investigate the association between miRNAs and lncRNA DANCR.
Statistical analysis. Paired t-test was used to compare the expression levels of DANCR in matched tumor/normal tissues and cells. Student's t-test was used to analyze assays for characterizing phenotypes of cells. All the statistical analysis was carried out by SPSS 19.0 statistical software package (SPSS, Inc., Chicago, IL, USA). The results are expressed as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference. 
Results
LncRNA DANCR is downregulated in RCC tissues. qPCR was performed to detect the expression level of DANCR in tissues.
The results [Log2 ratio (T/N)] are presented in Fig. 1A , which indicated that DANCR is downregulated in 17 RCC tissues compared with adjacent normal tissues. The expression levels of DANCR in RCC and normal tissues are presented in Fig. 1B . The results demonstrated DANCR was significantly downregulated in RCC tissues compared with paired adjacent normal tissues (P<0.01).
Validation of the expression of lncRNA DANCR following transfection. Following transfection of pcDNA3.1-DANCR or mock (empty pcDNA3.1), qPCR was performed to detect the expression of DANCR. The results demonstrated that expression of lncRNA DANCR was 119.84 times (786-O cell, P<0.001) and 175.73 times (ACHN cell, P<0.01) higher in cells transfected with pcDNA3.1-DANCR than in cells transfected with the mock (Fig. 2 ).
Overexpression of DANCR suppresses cell proliferation.
The results of the CCK-8 and MTT assays are presented in Fig. 3 .
In 786-O cells, the proliferation ability was suppressed by 6.91% (48 h, P<0.01) and 8.56% (72 h, P<0.01) for the CCK-8 assay (Fig. 3A) , and by 7.30% (48 h, P<0.05) and 8.00% (72 h, P<0.001) for the MTT assay, (Fig. 3B ) in cells transfected with pcDNA3.1-DANCR compared with cells transfected with the mock. In ACHN cells, overexpression of DANCR suppressed the cell proliferative ability by 9.44% (24 h, P<0.05), 10.24% (48 h, P<0.01) and 12.04% (72 h, P<0.001) for the CCK-8 assay (Fig. 3C ) and by 7.74% (24 h, P<0.05), 9.86% (48 h, P<0.01) and 9.03% (72 h, P<0.001) for the MTT assay (Fig. 3D) . Therefore, the results revealed that lncRNA DANCR could inhibit RCC cell proliferation.
Overexpression of lncRNA DANCR inhibits RCC cell mobility.
Cell scratch, Transwell migratory and Transwell invasive assays were performed to assess cell mobility ability. The results of the cell scratch assay revealed that overexpression of DANCR suppressed cell mobility ability by 25.38% for 786-O cells (P<0.01; Fig. 4A ) and 60.47% for ACHN cells (P<0.01; Fig. 4B ).
The results of the Transwell assay demonstrated that in 786-O cells, overexpression of DANCR suppressed the cell invasive ability by 32.10% (P<0.001) and the migratory ability by 34.13% (P<0.001; Fig. 5A ). In ACHN cells invasive ability was reduced by 31.03% (P<0.001) and migratory ability was reduced by 32.84% (P<0.001; Fig. 5B ). The results indicated that lncRNA DANCR could suppress RCC cell mobility.
Overexpression of lncRNA DANCR induces cell apoptosis.
The apoptotic rate was determined by flow cytometry. The results of flow cytometry indicated that apoptotic rate in 786-O cells transfected with pcDNA3.1-DANCR or mock was 41.03 vs. 11.58%, respectively (P<0.01, Fig. 6A ). In ACHN cells, the apoptosis rate of cells transfected with pcDNA3.1-DANCR or mock was 32.48 vs. 14.76%, respectively (P<0.01, Fig. 6B ). The results revealed that DANCR could induce cell apoptosis in RCC. miRNA prediction. The results predicted by the miRDB database, 15 miRNAs were predicted to target lncRNA DANCR. The miRNAs with highest scores, miR-3646 and miR-634, have been demonstrated to be associated with tumorigenesis. Therefore, miR-3646 and miR-634 may be regulators of lncRNA DANCR.
Discussion
Accumulating evidence has indicated that lncRNAs are dysregulated in various tumors, are involved in most cellular processes (15, 16) and have marked tissue-specific expression features (17) . A previous microarray study of RCC revealed 27,279 lncRNAs in RCC, of which 897 lncRNAs were dysregulated (18) . In another study, Blondeau et al (19) lncRNA DANCR, 855 bp in length, was previously termed anti-differentiation non-coding RNA (ANCR) (20) . A previous study revealed that lncRNA DANCR was upregulated in prostate cancer (11) , hepatocellular carcinoma (12) and CRC (13). Jia et al (11) demonstrated that DANCR could promote the invasion of prostate cancer cells by silencing expression of tissue inhibitor of matrix metalloproteinase 2/3. In CRC, high expression of DANCR was reported to be associated with advanced tumor progression and poor prognosis (13) , which indicated that DANCR may be a novel biomarker for CRC. Yuan et al (12) revealed that DANCR was upregulated in HCC and could increase the stemness features of HCC via upregulation of β-catenin. In the present study, DANCR was demonstrated to be downregulated in RCC tissues compared with adjacent normal tissues, which indicated that DANCR may have different functions in RCC. Subsequently experiments demonstrated that DANCR serves a role as a tumor suppressor in RCC by inhibiting RCC cell proliferation, migration and invasion, and inducing apoptosis. The database miRDB (http://mirdb.org/miRDB/index.html) predicted that microRNA (miR)-3646 and miR-634 might be regulators of DANCR. The associated miRNAs and downstream effectors require further investigation in future studies.
DANCR has also been demonstrated to serve an important role in non-cancer pathological processes. A study reported that DANCR could suppress odontoblast-like differentiation through inhibiting the Wnt/β-catenin signaling pathway (21) . Another study revealed that in patients with postmenopausal osteoporosis, DANCR was upregulated in blood monocytes and could negatively regulate interleukin-6 and tumor necrosis factor-α expression (22) . DANCR could also be an intermediary agent in some physiological processes. For example, SRY-box 4 could enhance chondrogenic differentiation and proliferation of human synovium-derived stem cell by activating DANCR (23) .
In conclusion, the present study revealed that DANCR is downregulated in RCC tissues. From the in vitro experiments, overexpression of DANCR served an important role in inhibiting cellular proliferation, migration and invasion, and inducing apoptosis. To the best of our knowledge, DANCR was demonstrated as a tumor suppressor for the first time. Therefore, DANCR may represent a potential biomarker for RCC, and further studies should be focused on the clinical significance and the signaling pathway of DANCR.
